SCHEMBL3549499

SCHEMBL3549499

Cc1ccc(-c2oncc2C(=O)N2CCC(c3ccc(C(F)(F)F)cc3)C2)cc1

nearest known ligand 0.46

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
HCRTR1 O43613 2/20 0.46
HCRTR2 O43614 2/20 0.46
PROKR1 Q8TCW9 3/20 0.44
FASN P49327 3/20 0.44
TRPV1 Q8NER1 1/20 0.43
TP53 P04637 3/20 0.42
RAB9A P51151 3/20 0.41
MAPT P10636 2/20 0.41
NPC1 O15118 2/20 0.41
LMNA P02545 1/20 0.41
KDM1A O60341 1/20 0.41
LIPE Q05469 1/20 0.41
TSHR P16473 2/20 0.41
SMN1; SMN2 Q16637 1/20 0.41
SCD5 Q86SK9 1/20 0.40
KDM4E B2RXH2 1/20 0.40
MEN1 O00255 1/20 0.40
KMT2A Q03164 1/20 0.40
HTT P42858 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3544988 1.00 HCRTR1 (0.46) HCRTR1HCRTR2PROKR1FASNTRPV1
SCHEMBL3555064 0.95 TRPV1 (0.46) HCRTR1HCRTR2PROKR1FASNTRPV1
SCHEMBL3554777 0.92 HCRTR1 (0.52) HCRTR1HCRTR2PROKR1TP53RAB9A
SCHEMBL3543644 0.91 NPC1 (0.46) HCRTR1HCRTR2PROKR1FASNTRPV1
SCHEMBL3544553 0.90 TRPV1 (0.47) HCRTR1HCRTR2PROKR1TRPV1TP53
SCHEMBL3546907 0.90 NAMPT (0.45) HCRTR1HCRTR2PROKR1FASNTRPV1
SCHEMBL3549119 0.90 FASN (0.46) HCRTR1HCRTR2PROKR1FASNTRPV1
SCHEMBL3546658 0.89 RAB9A (0.53) HCRTR1HCRTR2PROKR1TP53RAB9A
SCHEMBL3553605 0.88 HCRTR1 (0.48) HCRTR1HCRTR2PROKR1TP53RAB9A
SCHEMBL3542550 0.87 PROKR1 (0.50) HCRTR1HCRTR2PROKR1FASNTP53

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7666888-B2 Substituted azole aromatic heterocycles as inhibitors of 11β-HSD-1 AMGEN INC. (US) 2010-02-23 US disclosed
US-7666888-B2 Substituted azole aromatic heterocycles as inhibitors of 11β-HSD-1 AMGEN INC. (US) 2010-02-23 US disclosed
US-7666888-B2 Substituted azole aromatic heterocycles as inhibitors of 11β-HSD-1 AMGEN INC. (US) 2010-02-23 US disclosed
EP-2051977-A2 SUBSTITUTED AZOLE AROMATIC HETEROCYCLES AS INHIBITORS OF LLbeta-HSD-1 Amgen Inc. (US) 2009-04-29 EP disclosed
WO-2008011453-A2 SUBSTITUTED AZOLE AROMATIC HETEROCYCLES AS INHIBITORS OF LLβ-HSD-1 AMGEN INC. (US) 2008-01-24 WO disclosed
WO-2008011453-A2 SUBSTITUTED AZOLE AROMATIC HETEROCYCLES AS INHIBITORS OF LLβ-HSD-1 AMGEN INC. (US) 2008-01-24 WO disclosed
US-20080021022-A1 SUBSTITUTED AZOLE AROMATIC HETEROCYCLES AS INHIBITORS OF 11BETA-HSD-1 AMGEN INC. 2008-01-24 US disclosed
US-20080021022-A1 SUBSTITUTED AZOLE AROMATIC HETEROCYCLES AS INHIBITORS OF 11BETA-HSD-1 AMGEN INC. 2008-01-24 US disclosed
US-20080021022-A1 SUBSTITUTED AZOLE AROMATIC HETEROCYCLES AS INHIBITORS OF 11BETA-HSD-1 AMGEN INC. 2008-01-24 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080021022-A1 SUBSTITUTED AZOLE AROMATIC HETEROCYCLES AS INHIBITORS OF 11BETA-HSD-1 HSD17B1, HSD11B1, HSD17B11 HCRTR1 314/4885HCRTR2 531/4885PROKR1 878/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.